A new look at the prognostic value of the estrogen, progesterone and epidermal growth factor receptors in breast cancer tissue

Neoplasma

Volumn 52, Issue 1, 2005, Pages 10-17

  Skasko, E ^a   Paszko, Z ^a   Mazur, S ^a  

^a INSTITUTE OF ONCOLOGY   (Poland)

Author keywords

Epidermal growth factor; Estrogen; Progesterone; Receptors; Survival

Indexed keywords

16ALPHA ETHYL 21 HYDROXY 19 NORPREGN 4 ENE 3,20 DIONE; DIETHYLSTILBESTROL; EPIDERMAL GROWTH FACTOR RECEPTOR; ESTRADIOL; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; TRITIUM;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER SURVIVAL; DISEASE FREE SURVIVAL; FEMALE; HISTOPATHOLOGY; HORMONE RECEPTOR INTERACTION; HUMAN; HUMAN TISSUE; INTRADUCTAL CARCINOMA; ISOTOPE LABELING; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; POSTMENOPAUSE; PREMENOPAUSE; PROGNOSIS;

EID: 14744271946     PISSN: 00282685     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. AZIZ SA, PERVEZ S, KHAN S, KAYANI N, RAHBAR MH. Epidermal growth factor receptor (EGFR) as a prognostic marker: an immunohistochemical study on 315 consecutive breast carcinoma patients. J Pak Med Assoc 2002; 52: 104-110.
2. BASELGA J. The EGFR as a target for anticancer therapy - focus on cetuximab. Eur J Cancer 2001; 37: S16-S22.
3. CASTAGNETTA L, TRAINA A, AGOSTARA B, MIELE M, CAMPISI I et al. Ligand binding and cytochemical analysis of estrogen and progesterone receptors in relation to follow-up in patients with breast cancer. Ann N Y Acad Sci 2000; 963: 98-103.
4. DICKSON RB, STANCEL GM. Estrogen Receptor-Mediated Processes in Normal and Cancer Cells. J Natl Cancer Inst Monogr 1999; 27: 135-145.
5. FERRERO JM, RAMAIOLI A, LARGILLIER R, FORMENTO JL, FRANCOUAL M et al. Epidermal growth factor receptor expression in 780 breast cancer patients: a reappraisal of the prognostic value based on an eight-year median follow-up. Ann Oncol 2001; 12: 841-846.
6. FOX SB, SMITH K, HOLLYER J, GREENALL M, HASTRICH D et al. The epidermal growth factor receptor as a prognostic factor: results of 370 patients and review of 3009 patients. Breast Cancer Res Treat 1994; 29: 41-49.
7. HARRIS AL, NICHOLSON S, SAINSBURY JRC, FARNDON J, WRIGHT C. Epidermal growth factor receptors in breast cancer: association with early relapse and death, poor response to hormones and interactions with neu. J Steroid Biochem 1989; 34: 123-131.
8. HERBST RS, SHIN DM. Monoclonal Antibodies to target epidermal growth factor receptor-positive tumors. Cancer 2002; 94: 1593-1611.
9. KLIJN JGM, BERNS PMJJ, SCHMITZ PIM, FOEKENS JA. The clinical significance of epidermal growth factor receptor in human breast cancer: a review on 5332 patients. Endocrine Rev 1992; 13: 3-17.
10. KOENDERS PG, BEEX LUAM, KIENHUIS CBM, KLOPPENBORG PW, BENRAAD T. Epidermal growth factor receptor and prognosis in human breast cancer: A prospective study. Breast Cancer Res Treat 1993; 25: 21-27.
11. LOWRY H, ROSEBROUGH NJ, FARR AL, RANDALL RJ. Protein measurement with Folin phenol reagent. J Biol Chem 1951; 193: 265-275.
12. MAURI FA, MAISONNEUVE P, CAFFO O, VERONESE S, ALDOVINI D et al. Prognostic value of estrogen receptor status can be improved by combined evaluation of p53, Bcl2 and PgR expression: an immunohistochemical study on breast carcinoma with long-term follow-up. Int J Oncol 1999; 15: 1137-114.
13. MAZUR S, PASZKO z, SKASKO E, OLSZEWSKI W. The survival rate of women with breast cancer and the concentration of ER, PR and EGF-R in primary tumour. Presented at XIX PTO Congress, Gdansk, 1998; September 10-12.
14. MENDELSOHN J, BASELGA J. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncology 2003; 21: 2787-2799.
15. NASRALLA MY, PASZKO Z, OMAR YT, ALIMA A, ALJAZZAF H et al. The relationship between epidermal growth factor receptor and oestrogen and progesterone receptors in breast cancers of premenopausal and postmenopausal patients in Kuwait. Eur J Cancer 1993; 29A: 76-81.
16. NICHOLSON S, HALCROW P, SAINSBURY JRC, ANGUS B, CHAMBERS P et al. Epidermal growth factor receptor (EGFr); results of a 6 year follow-up study in operable breast cancer with emphasis on the node negative subgroup. Br J Cancer 1991; 63: 140-150.
17. PAECH K, WEBB P, KUIPER GGJM, NILSSON S, GUSTAFSSON J et al. Differential ligand activation of estrogen receptors ERα and ERβ at AP1 sites. Science 1997; 277: 1508-1510.
18. PASZKO Z, MAZUR S, WISNIEWSKA A, SKASKO E. Relationships between simultaneous occurrence or lack of estrogens, progesterone and epidermal growth factor receptors in breast versus the survival of patients with breast cancer. Presented at XIX PTO Congress, Gdansk, 1998; September 10-12.
19. PASZKO Z, PADZIK H, DABSKA M, PIENKOWSKA F. Estrogen receptor in human breast cancer in relation to tumor morphology and endocrine therapy. Tumori 1978; 64: 495-50.
20. SAINSBURY JRC, FARNDON JR, NEEDHAM GK, MALCOLM AJ, HARRIS AL. Epidermal-growth factor receptor status as predictor of early recurrence of and death from breast cancer. Lancet 1987; 1: 1398-1402.
21. SAINSBURY JRC, NICHOLSON S, ANGUS B, FARNDON JR, MALCOLM AJ et al. Epidermal growth factor receptor status of histological sub-types of breast cancer. Br J Cancer 1988; 58: 458-446.
22. SKASKO E, PASZKO z, BIELINSKA B, KLUSKA A. Epidermal growth factor receptor and estrogen and progesterone receptors in breast cancers of premenopausal and postmenopausal patients. Tumori 1994; 80: 56-60.
23. TORREGROSA D, BOLUFER P, LLUCH A, LOPEZ JA, BARRAGAN E et al. Prognostic significance of c-erbB-2/neu amplification and epidermal growth factor receptor (EGFR) in primary breast cancer and their relation to estradiol receptor (ER) status. Clin Chimica Acta 1997; 262: 99-119.
24. TSUTSUI S, KATAOKA A, OHNO S, MURAKAMI S, KINOSHITA J et al. Prognostic and predictive value of epidermal growth factor receptor in recurrent breast cancer. Clin Cancer Res 2002; 8: 3454-3460.
25. TSUTSUI S, OHNO S, MURAKAMI S, HACHITANDA Y, ODA S. Prognostic value of epidermal growth factor receptor (EGFR) and its relationship to the estrogen receptor status in 1029 patients with breast cancer. Breast Cancer Res Treat 2002; 71: 67-75.